Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-10-16

Adaptive Biotechnologies Corp (ADPT)

CEO Chad Robins was paid $9,081,690 in fiscal year 2025, ↑ up 82.6% from fiscal year 2024, the 75th percentile of its disclosed peer group (SEC filing 0001193125-26-177409 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$9,081,690 ↑
Chad Robins total, FY2025
75th
CEO pay percentile vs peers
47:1
CEO-to-median pay ratio
96.67%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Chad Robins (Chief Executive Officer and Chairman), FY2025 total compensation $9,081,690 (base salary $698,258) [exec_comp, SEC accession 0001193125-26-177409, filed 2026-04-24]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

ADPT's next annual pay disclosure, estimated April 24, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Chad Robins$698,258$0$7,675,100$0$703,380$0$4,952$9,081,690
Chief Executive Officer and Chairman
Harlan Robins558,653—7,675,100—270,823—4,9998,509,575
Chief Scientific Officer
Julie Rubinstein542,38303,783,5000273,18004,9324,603,995
President and Chief Operating Officer
Susan Bobulsky435,75001,883,990997,325226,01304,4803,547,558
Chief Commercial Officer, MRD
Kyle Piskel399,95002,702,5000203,30004,9793,310,729
Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Chad Robins$9,081,690$4,973,301$8,904,267↑ +4,108,389
Harlan Robins8,509,5754,540,2868,611,805↑ +3,969,289
Julie Rubinstein4,603,9952,644,5532,971,039↑ +1,959,442
Susan Bobulsky3,547,5581,706,7001,455,155↑ +1,840,858
Kyle Piskel3,310,7291,290,346744,046↑ +2,020,383

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Adaptive Biotechnologies Corp's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ADPT reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

Get the Adaptive Biotechnologies Corp Peer Teardown Report

$9,081,690 Chad Robins total, FY2025

$199

The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.

Data as of October 16, 2026 · Source: 0001193125-26-177409 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

Reports for ADPT

Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:

Executive Compensation ReportThe free page is the headline figures. The report is every award, peer and vote combined into one document you can hand to a committee.$1,500 →Reverse Peer AnalysisThe free page is the one line. The analysis reads every company that names this one in its own peer group.$299 →Peer Teardown ReportThe free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.$199 →
ADPTon Velarion Intel, free → The platform reading of this company, beside the same data as a subscription.

Order ADPT

Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

How we handle your data → Privacy

Companies that benchmark against ADPT
16 companies name ADPT as a compensation peer

Each company listed discloses ADPT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ADPT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Get the Adaptive Biotechnologies Corp Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Katey OwenIndependent Director$309,997
Michael PelliniFormer director (through FY2025)$276,463
Michelle GriffinIndependent Director$329,997
Peter NeupertLead Independent Director$354,997
Robert HershbergIndependent Director$324,997
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Julie RubinsteinPresident and COO2026-04-24D14,722$0$0Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-04-24D19,06014267,221CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-04-24A14,7228124,548CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-04-27A14,7078124,421CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-04-27D14,70700Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-04-27D19,03714270,897CommonForm 4 ↗
Kyle PiskelChief Financial Officer2026-05-18D3,1151340,620CommonForm 4 ↗
Francis LoChief People Officer2026-06-04A2,009816,996CommonForm 4 ↗
Francis LoChief People Officer2026-06-04A2,34449,353CommonForm 4 ↗
Francis LoChief People Officer2026-06-04D39,74117695,070CommonForm 4 ↗
Francis LoChief People Officer2026-06-04A9,376876,133CommonForm 4 ↗
Francis LoChief People Officer2026-06-04A5,7921270,315CommonForm 4 ↗
Susan BobulskyChief Commercial Officer, MRD2026-06-04D11,00018198,000CommonForm 4 ↗
Francis LoChief People Officer2026-06-04D9,37600Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-06-04D2,34400Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-06-04D2,00900Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-06-04D5,79200Derivative, Class A CommonForm 4 ↗
Susan BobulskyChief Commercial Officer, MRD2026-06-11D5,0001995,000CommonForm 4 ↗
Harlan S. RobinsChief Scientific Officer2026-06-15D100,000171,737,000CommonForm 4 ↗
Harlan S. RobinsChief Scientific Officer2026-06-16D6,16018110,942CommonForm 4 ↗
Michelle GriffinDirector2026-06-25D52,08400Derivative, Class A CommonForm 4 ↗
Michelle GriffinDirector2026-06-25D52,084201,051,055CommonForm 4 ↗
Michelle GriffinDirector2026-06-25A52,0848406,255CommonForm 4 ↗
Susan BobulskyChief Commercial Officer, MRD2026-06-25D5,00021102,500CommonForm 4 ↗
Sharon BenzenoChief Commercial Ofc Imm Med2026-06-26A11,03412133,953CommonForm 4 ↗
Sharon BenzenoChief Commercial Ofc Imm Med2026-06-26D11,03400Derivative, Class A CommonForm 4 ↗
Sharon BenzenoChief Commercial Ofc Imm Med2026-06-26D11,03421231,714CommonForm 4 ↗
Dividend-equivalent accruals2026-06-29—1,837——1 insider, 1 accrual row
Sharon BenzenoChief Commercial Ofc Imm Med2026-06-29D51,57000Derivative, Class A CommonForm 4 ↗
Sharon BenzenoChief Commercial Ofc Imm Med2026-06-29D24,94400Derivative, Class A CommonForm 4 ↗
Sharon BenzenoChief Commercial Ofc Imm Med2026-06-29A51,5708418,748CommonForm 4 ↗
Sharon BenzenoChief Commercial Ofc Imm Med2026-06-29D154,768213,271,796CommonForm 4 ↗
Sharon BenzenoChief Commercial Ofc Imm Med2026-06-29A24,9448211,026CommonForm 4 ↗
Sharon BenzenoChief Commercial Ofc Imm Med2026-06-29A1,8371222,301CommonForm 4 ↗
Sharon BenzenoChief Commercial Ofc Imm Med2026-06-29D24,94400Derivative, Class A CommonForm 4 ↗
Sharon BenzenoChief Commercial Ofc Imm Med2026-06-29A24,944499,527CommonForm 4 ↗
Francis LoChief People Officer2026-07-01A3,500827,300CommonForm 4 ↗
Susan BobulskyChief Commercial Officer, MRD2026-07-01D4872210,714CommonForm 4 ↗
Francis LoChief People Officer2026-07-01D8,74322193,920CommonForm 4 ↗
Francis LoChief People Officer2026-07-01D14,06400Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-07-01A14,0648114,200CommonForm 4 ↗
Francis LoChief People Officer2026-07-01A4,688418,705CommonForm 4 ↗
Francis LoChief People Officer2026-07-01A12,2068103,263CommonForm 4 ↗
Francis LoChief People Officer2026-07-01A3,3001240,062CommonForm 4 ↗
Francis LoChief People Officer2026-07-01D4,68800Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-07-01D12,20600Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-07-01D3,30000Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-07-01D3,50000Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-07-01D42,26123950,873CommonForm 4 ↗
Francis LoChief People Officer2026-07-02D44,838231,012,890CommonForm 4 ↗
Francis LoChief People Officer2026-07-02A12,60012152,964CommonForm 4 ↗
Harlan S. RobinsChief Scientific Officer2026-07-02D146,889223,297,658CommonForm 4 ↗
Francis LoChief People Officer2026-07-02D12,62600Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-07-02A12,6378106,909CommonForm 4 ↗
Francis LoChief People Officer2026-07-02A12,626898,483CommonForm 4 ↗
Harlan S. RobinsChief Scientific Officer2026-07-02D239,351225,203,491CommonForm 4 ↗
Francis LoChief People Officer2026-07-02D12,63700Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-07-02D12,60000Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-07-15D105,762232,389,164CommonForm 4 ↗
Francis LoChief People Officer2026-07-15A22,7118192,135CommonForm 4 ↗
Francis LoChief People Officer2026-07-15D22,71100Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-07-15D23,67700Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-07-15D59,37400Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-07-15A23,67712287,439CommonForm 4 ↗
Francis LoChief People Officer2026-07-15A59,3748463,117CommonForm 4 ↗
Susan BobulskyChief Commercial Officer, MRD2026-07-16D5,00023115,000CommonForm 4 ↗
Harlan S. RobinsChief Scientific Officer2026-07-21D284,80000Derivative, Class A CommonForm 4 ↗
Harlan S. RobinsChief Scientific Officer2026-07-21D213,702224,727,088CommonForm 4 ↗
Harlan S. RobinsChief Scientific Officer2026-07-21D278,698226,053,321CommonForm 4 ↗
Harlan S. RobinsChief Scientific Officer2026-07-21A284,80071,865,440CommonForm 4 ↗
Susan BobulskyChief Commercial Officer, MRD2026-07-30D1,2992431,176CommonForm 4 ↗
Susan BobulskyChief Commercial Officer, MRD2026-08-10D3,0002575,000CommonForm 4 ↗
Peter NeupertDirector2026-08-17D15,00000Derivative, Class A CommonForm 4 ↗
Peter NeupertDirector2026-08-17D69,690251,753,400CommonForm 4 ↗
Peter NeupertDirector2026-08-17D15,00025378,450CommonForm 4 ↗
Peter NeupertDirector2026-08-17A15,000694,800CommonForm 4 ↗
Chad M. RobinsDirector2026-08-17D321,32400Derivative, Class A CommonForm 4 ↗
Chad M. RobinsDirector2026-08-17D318,799257,995,479CommonForm 4 ↗
Peter NeupertDirector2026-08-17D40,000251,004,000CommonForm 4 ↗
Chad M. RobinsDirector2026-08-17D2,5252664,564CommonForm 4 ↗
Chad M. RobinsDirector2026-08-17A321,32472,104,672CommonForm 4 ↗
Chad M. RobinsDirector2026-08-18D278,67600Derivative, Class A CommonForm 4 ↗
Chad M. RobinsDirector2026-08-18D204255,129CommonForm 4 ↗
Chad M. RobinsDirector2026-08-18D278,472246,816,995CommonForm 4 ↗
Chad M. RobinsDirector2026-08-18A278,67671,825,328CommonForm 4 ↗
Robert HershbergDirector2026-08-18D15,00000Derivative, Class A CommonForm 4 ↗
Robert HershbergDirector2026-08-18D15,66424382,358CommonForm 4 ↗
Robert HershbergDirector2026-08-18D15,00024365,850CommonForm 4 ↗
Robert HershbergDirector2026-08-18A15,000694,800CommonForm 4 ↗
Katey OwenDirector2026-08-26D9,61526249,990CommonForm 4 ↗
Katey OwenDirector2026-08-31D12,539——CommonForm 4 ↗
Susan BobulskyChief Commercial Officer, MRD2026-09-15D1,1952732,265CommonForm 4 ↗
Francis LoChief People Officer2026-09-16D53,09100Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-09-16D107,537283,013,187CommonForm 4 ↗
Francis LoChief People Officer2026-09-16A23,4428190,349CommonForm 4 ↗
Francis LoChief People Officer2026-09-16D23,44200Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-09-16D15,62900Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-09-16D13,39800Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-09-16D7,86929224,817CommonForm 4 ↗
Francis LoChief People Officer2026-09-16A15,629462,360CommonForm 4 ↗
Francis LoChief People Officer2026-09-16A13,3988113,347CommonForm 4 ↗
Francis LoChief People Officer2026-09-16A53,09112644,525CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-01D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-01A11,88112144,235CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-01D6,08128167,653CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-01D5,80029165,648CommonForm 4 ↗
Francis LoChief People Officer2026-10-01D9,37700Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-10-01D9,37700Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-10-01D8,03800Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-10-01D18,69829534,950CommonForm 4 ↗
Francis LoChief People Officer2026-10-01D8,09428222,747CommonForm 4 ↗
Francis LoChief People Officer2026-10-01A9,377876,141CommonForm 4 ↗
Francis LoChief People Officer2026-10-01A9,377437,414CommonForm 4 ↗
Francis LoChief People Officer2026-10-01A8,038868,001CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-02D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-02D11,88128334,213CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-02A11,88112144,235CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-05D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-05D5,18230153,750CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-05A11,88112144,235CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-05D6,69929193,065CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-06D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-06D9013026,769CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-06D1,1002831,031CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-06D9,38127256,664CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-06A11,88112144,235CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-06D4993115,234CommonForm 4 ↗
Susan BobulskyChief Commercial Officer, MRD2026-10-06D6,44430193,320CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-07D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-07A11,88112144,235CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-07D11,88126313,658CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-08D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-08D11,88126304,866CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-08A11,88112144,235CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-09D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-09D11,88126313,777CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-09A11,88112144,235CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-12D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-12D2,7002670,389CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-12D9,18125232,738CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-12A11,88112144,235CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-13D11,88126302,966CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-13A11,88112144,235CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-13D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-14D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-14D5,10026131,682CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-14D6,78126173,390CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-14A11,88112144,235CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-15D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-15D11,88126304,272CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-15A11,88112144,235CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-16D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-16D300257,635CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-16D11,58124280,376CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-16A11,88112144,235CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 155 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Julie RubinsteinPresident and COO2026-04-24D14,722$0$0Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-04-24D19,06014267,221CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-04-24A14,7228124,548CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-04-27A14,7078124,421CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-04-27D14,70700Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-04-27D19,03714270,897CommonForm 4 ↗
Kyle PiskelChief Financial Officer2026-05-18D3,1151340,620CommonForm 4 ↗
Francis LoChief People Officer2026-06-04A2,009816,996CommonForm 4 ↗
Francis LoChief People Officer2026-06-04A2,34449,353CommonForm 4 ↗
Francis LoChief People Officer2026-06-04D39,74117695,070CommonForm 4 ↗
Francis LoChief People Officer2026-06-04A9,376876,133CommonForm 4 ↗
Francis LoChief People Officer2026-06-04A5,7921270,315CommonForm 4 ↗
Susan BobulskyChief Commercial Officer, MRD2026-06-04D11,00018198,000CommonForm 4 ↗
Francis LoChief People Officer2026-06-04D9,37600Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-06-04D2,34400Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-06-04D2,00900Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-06-04D5,79200Derivative, Class A CommonForm 4 ↗
Susan BobulskyChief Commercial Officer, MRD2026-06-11D5,0001995,000CommonForm 4 ↗
Harlan S. RobinsChief Scientific Officer2026-06-15D100,000171,737,000CommonForm 4 ↗
Harlan S. RobinsChief Scientific Officer2026-06-16D6,16018110,942CommonForm 4 ↗
Michelle GriffinDirector2026-06-25D52,08400Derivative, Class A CommonForm 4 ↗
Michelle GriffinDirector2026-06-25D52,084201,051,055CommonForm 4 ↗
Michelle GriffinDirector2026-06-25A52,0848406,255CommonForm 4 ↗
Susan BobulskyChief Commercial Officer, MRD2026-06-25D5,00021102,500CommonForm 4 ↗
Sharon BenzenoChief Commercial Ofc Imm Med2026-06-26A11,03412133,953CommonForm 4 ↗
Sharon BenzenoChief Commercial Ofc Imm Med2026-06-26D11,03400Derivative, Class A CommonForm 4 ↗
Sharon BenzenoChief Commercial Ofc Imm Med2026-06-26D11,03421231,714CommonForm 4 ↗
Sharon BenzenoChief Commercial Ofc Imm Med2026-06-29D1,83700Derivative, Class A CommonForm 4 ↗
Sharon BenzenoChief Commercial Ofc Imm Med2026-06-29D51,57000Derivative, Class A CommonForm 4 ↗
Sharon BenzenoChief Commercial Ofc Imm Med2026-06-29D24,94400Derivative, Class A CommonForm 4 ↗
Sharon BenzenoChief Commercial Ofc Imm Med2026-06-29A51,5708418,748CommonForm 4 ↗
Sharon BenzenoChief Commercial Ofc Imm Med2026-06-29D154,768213,271,796CommonForm 4 ↗
Sharon BenzenoChief Commercial Ofc Imm Med2026-06-29A24,9448211,026CommonForm 4 ↗
Sharon BenzenoChief Commercial Ofc Imm Med2026-06-29A1,8371222,301CommonForm 4 ↗
Sharon BenzenoChief Commercial Ofc Imm Med2026-06-29D24,94400Derivative, Class A CommonForm 4 ↗
Sharon BenzenoChief Commercial Ofc Imm Med2026-06-29A24,944499,527CommonForm 4 ↗
Francis LoChief People Officer2026-07-01A3,500827,300CommonForm 4 ↗
Susan BobulskyChief Commercial Officer, MRD2026-07-01D4872210,714CommonForm 4 ↗
Francis LoChief People Officer2026-07-01D8,74322193,920CommonForm 4 ↗
Francis LoChief People Officer2026-07-01D14,06400Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-07-01A14,0648114,200CommonForm 4 ↗
Francis LoChief People Officer2026-07-01A4,688418,705CommonForm 4 ↗
Francis LoChief People Officer2026-07-01A12,2068103,263CommonForm 4 ↗
Francis LoChief People Officer2026-07-01A3,3001240,062CommonForm 4 ↗
Francis LoChief People Officer2026-07-01D4,68800Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-07-01D12,20600Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-07-01D3,30000Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-07-01D3,50000Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-07-01D42,26123950,873CommonForm 4 ↗
Francis LoChief People Officer2026-07-02D44,838231,012,890CommonForm 4 ↗
Francis LoChief People Officer2026-07-02A12,60012152,964CommonForm 4 ↗
Harlan S. RobinsChief Scientific Officer2026-07-02D146,889223,297,658CommonForm 4 ↗
Francis LoChief People Officer2026-07-02D12,62600Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-07-02A12,6378106,909CommonForm 4 ↗
Francis LoChief People Officer2026-07-02A12,626898,483CommonForm 4 ↗
Harlan S. RobinsChief Scientific Officer2026-07-02D239,351225,203,491CommonForm 4 ↗
Francis LoChief People Officer2026-07-02D12,63700Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-07-02D12,60000Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-07-15D105,762232,389,164CommonForm 4 ↗
Francis LoChief People Officer2026-07-15A22,7118192,135CommonForm 4 ↗
Francis LoChief People Officer2026-07-15D22,71100Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-07-15D23,67700Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-07-15D59,37400Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-07-15A23,67712287,439CommonForm 4 ↗
Francis LoChief People Officer2026-07-15A59,3748463,117CommonForm 4 ↗
Susan BobulskyChief Commercial Officer, MRD2026-07-16D5,00023115,000CommonForm 4 ↗
Harlan S. RobinsChief Scientific Officer2026-07-21D284,80000Derivative, Class A CommonForm 4 ↗
Harlan S. RobinsChief Scientific Officer2026-07-21D213,702224,727,088CommonForm 4 ↗
Harlan S. RobinsChief Scientific Officer2026-07-21D278,698226,053,321CommonForm 4 ↗
Harlan S. RobinsChief Scientific Officer2026-07-21A284,80071,865,440CommonForm 4 ↗
Susan BobulskyChief Commercial Officer, MRD2026-07-30D1,2992431,176CommonForm 4 ↗
Susan BobulskyChief Commercial Officer, MRD2026-08-10D3,0002575,000CommonForm 4 ↗
Peter NeupertDirector2026-08-17D15,00000Derivative, Class A CommonForm 4 ↗
Peter NeupertDirector2026-08-17D69,690251,753,400CommonForm 4 ↗
Peter NeupertDirector2026-08-17D15,00025378,450CommonForm 4 ↗
Peter NeupertDirector2026-08-17A15,000694,800CommonForm 4 ↗
Chad M. RobinsDirector2026-08-17D321,32400Derivative, Class A CommonForm 4 ↗
Chad M. RobinsDirector2026-08-17D318,799257,995,479CommonForm 4 ↗
Peter NeupertDirector2026-08-17D40,000251,004,000CommonForm 4 ↗
Chad M. RobinsDirector2026-08-17D2,5252664,564CommonForm 4 ↗
Chad M. RobinsDirector2026-08-17A321,32472,104,672CommonForm 4 ↗
Chad M. RobinsDirector2026-08-18D278,67600Derivative, Class A CommonForm 4 ↗
Chad M. RobinsDirector2026-08-18D204255,129CommonForm 4 ↗
Chad M. RobinsDirector2026-08-18D278,472246,816,995CommonForm 4 ↗
Chad M. RobinsDirector2026-08-18A278,67671,825,328CommonForm 4 ↗
Robert HershbergDirector2026-08-18D15,00000Derivative, Class A CommonForm 4 ↗
Robert HershbergDirector2026-08-18D15,66424382,358CommonForm 4 ↗
Robert HershbergDirector2026-08-18D15,00024365,850CommonForm 4 ↗
Robert HershbergDirector2026-08-18A15,000694,800CommonForm 4 ↗
Katey OwenDirector2026-08-26D9,61526249,990CommonForm 4 ↗
Katey OwenDirector2026-08-31D12,539——CommonForm 4 ↗
Susan BobulskyChief Commercial Officer, MRD2026-09-15D1,1952732,265CommonForm 4 ↗
Francis LoChief People Officer2026-09-16D53,09100Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-09-16D107,537283,013,187CommonForm 4 ↗
Francis LoChief People Officer2026-09-16A23,4428190,349CommonForm 4 ↗
Francis LoChief People Officer2026-09-16D23,44200Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-09-16D15,62900Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-09-16D13,39800Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-09-16D7,86929224,817CommonForm 4 ↗
Francis LoChief People Officer2026-09-16A15,629462,360CommonForm 4 ↗
Francis LoChief People Officer2026-09-16A13,3988113,347CommonForm 4 ↗
Francis LoChief People Officer2026-09-16A53,09112644,525CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-01D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-01A11,88112144,235CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-01D6,08128167,653CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-01D5,80029165,648CommonForm 4 ↗
Francis LoChief People Officer2026-10-01D9,37700Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-10-01D9,37700Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-10-01D8,03800Derivative, Class A CommonForm 4 ↗
Francis LoChief People Officer2026-10-01D18,69829534,950CommonForm 4 ↗
Francis LoChief People Officer2026-10-01D8,09428222,747CommonForm 4 ↗
Francis LoChief People Officer2026-10-01A9,377876,141CommonForm 4 ↗
Francis LoChief People Officer2026-10-01A9,377437,414CommonForm 4 ↗
Francis LoChief People Officer2026-10-01A8,038868,001CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-02D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-02D11,88128334,213CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-02A11,88112144,235CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-05D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-05D5,18230153,750CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-05A11,88112144,235CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-05D6,69929193,065CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-06D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-06D9013026,769CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-06D1,1002831,031CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-06D9,38127256,664CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-06A11,88112144,235CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-06D4993115,234CommonForm 4 ↗
Susan BobulskyChief Commercial Officer, MRD2026-10-06D6,44430193,320CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-07D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-07A11,88112144,235CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-07D11,88126313,658CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-08D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-08D11,88126304,866CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-08A11,88112144,235CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-09D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-09D11,88126313,777CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-09A11,88112144,235CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-12D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-12D2,7002670,389CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-12D9,18125232,738CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-12A11,88112144,235CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-13D11,88126302,966CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-13A11,88112144,235CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-13D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-14D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-14D5,10026131,682CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-14D6,78126173,390CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-14A11,88112144,235CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-15D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-15D11,88126304,272CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-15A11,88112144,235CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-16D11,88100Derivative, Class A CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-16D300257,635CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-16D11,58124280,376CommonForm 4 ↗
Julie RubinsteinPresident and COO2026-10-16A11,88112144,235CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Susan BobulskyRSU2025-03-04——119,971—$974,165
Susan BobulskyOPTION2025-03-04——180,029—997,325
Julie RubinsteinRSU2025-03-04——175,000—1,421,000
Harlan RobinsRSU2025-03-04——355,000—2,882,600
Kyle PiskelRSU2025-03-04——125,000—1,015,000
Chad RobinsRSU2025-03-04——355,000—2,882,600
Julie RubinsteinRSU2025-03-04——175,000—2,362,500
Chad RobinsRSU2025-03-04——355,000—4,792,500
Harlan RobinsRSU2025-03-04——355,000—4,792,500
Susan BobulskyRSU2025-03-14——124,976—909,825
Kyle PiskelRSU2025-03-04——125,000—1,687,500
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Susan Bobulsky$1,883,990$0$997,3250.0%
Julie Rubinstein3,783,500000.0%
Harlan Robins7,675,100000.0%
Kyle Piskel2,702,500000.0%
Chad Robins7,675,100000.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Kyle PiskelRSU21,868—$355,136
Kyle PiskelRSU250,000—4,060,000
Julie RubinsteinRSU350,000—5,684,000
RobinsRSU620,568—10,078,024
Kyle PiskelRSU10,297—167,223
RobinsRSU710,000—11,530,400
RobinsRSU531,916—8,638,316
Julie RubinsteinRSU306,250—4,973,500
Susan BobulskyRSU124,976—2,029,610
Kyle PiskelRSU98,445—1,598,747
Susan BobulskyRSU119,971—1,948,329
Julie RubinsteinRSU66,490—1,079,798
Susan BobulskyRSU99,735—1,619,696
RobinsRSU61,780—1,003,307
Julie RubinsteinRSU46,335—752,480
Kyle PiskelRSU32,805—532,753
Susan BobulskyRSU29,552—479,924
Susan BobulskyRSU10,297—167,223
Kyle PiskelOption6,43612.14—
Susan BobulskyOption6,43612.14—
Susan BobulskyOption27,7168.46—
Susan BobulskyOption112,2473.99—
Susan BobulskyOption180,0298.12—
RobinsOption38,61212.14—
Julie RubinsteinOption28,95912.14—
Julie RubinsteinOption62,3608.46—
05

Incentive-plan design — the Compensation Discussion & Analysis

The company targets total compensation at or near the market median of the peer group, with flexibility to adjust based on experience and performance. The program emphasizes pay-for-performance by delivering a majority of compensation through variable pay, with at least 50% of target compensation in equity and at least 50% of equity grants in the form of performance stock units (PSUs).

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantSemler Brossy Consulting Group, LLC
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-05125,287,6184,316,144158,59996.67%Passed
20252025-06-10126,126,9991,580,695397,86898.76%Passed
20242024-06-07103,594,01615,410,7441,454,95087.05%Passed
20232023-06-0989,592,58717,467,5291,294,42483.68%Passed
20222022-06-1072,717,58344,482,886298,41662.05%Passed
20212021-06-11100,345,2267,888,977146,57292.71%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-0596.67%a
20252025-06-1098.76%b
20242024-06-0787.05%c

a. Approved under the standard stated in the filing — “Abstentions are considered to be votes not cast on this proposal and thus will have no effect.”.

b. Approved under the standard stated in the filing — “Abstentions are considered to be votes not cast on this proposal and thus will have no effect.”.

c. Approved under the standard stated in the filing — “Abstentions are considered to be votes not cast on this proposal and thus will have no effect.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)47 : 1
CEO total compensation$9,081,690
Median employee compensation$194,620
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Peter NeupertIndependent · Lead Independent Director · Audit Committee · Compensation and Human Capital Committee · Nominating and Corporate Governance Committee (Chair)$105,000$124,999$124,998——$354,997
Michelle GriffinIndependent · Audit Committee (Chair)80,000124,999124,998——329,997
Robert HershbergIndependent · Compensation and Human Capital Committee (Chair) · Nominating and Corporate Governance Committee75,000124,999124,998——324,997
Katey OwenIndependent · Audit Committee · Compensation and Human Capital Committee60,000124,999124,998——309,997
Michael PelliniIndependent · Not standing for re-election · Departed during FY26,466124,999124,998——276,463
Chad RobinsEmployee director · Board Chair—————0
09

Board fee structure and ownership guideline

Annual cash retainer$60,000
Annual equity retainer$250,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline$180,000
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$346,466
Equity awards (grant-date value)$624,995
All other compensation$0
Total cost of the board$971,461

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Adaptive Biotechnologies Corp names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Adaptive Biotechnologies Corp.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Natera, Inc.2025Steven Chapman$853,710$12,979,558$0$1,114,151$14,957,319
2Twist Bioscience Corporation2025Emily Leproust720,00011,998,1340932,91813,781,570
3Immunocore Holdings plc2025Bahija Jallal765,0002,819,9926,579,990688,50010,885,268
4Maravai LifeSciences Holdings, Inc.2025Bernd Brust388,8637,660,0001,460,000425,34310,129,708
5NeoGenomics, Inc.2025Tony Zook601,5393,999,9973,998,235513,4009,127,092
6Adaptive Biotechnologies Corp2025Chad Robins698,2587,675,1000703,3809,081,690
7Guardant Health, Inc.2025AmirAli Talasaz18,647,709008,661,227
8Veracyte, Inc.2025Marc Stapley700,0005,890,8770826,0007,421,877
9CareDx, Inc.2025John Hanna693,2695,622,6380852,5157,179,699
10Sage Therapeutics, Inc.2024Barry Greene830,7123,164,3642,669,263431,9707,112,589
11Castle Biosciences, Inc.2025Derek Maetzold751,3504,977,20801,036,8636,786,771
12Mesa Laboratories, Inc.2026Gary Owens808,8464,700,01701,120,0006,643,208
13Fulgent Genetics, Inc.2025Ming Hsieh1,000,0004,000,00001,207,0006,207,000
14Allogene Therapeutics, Inc.2025David Chang724,0002,409,5372,588,329400,0106,136,093
15Myriad Genetics, Inc.2025Samraat Raha856,9013,989,7290814,6605,686,740
16Recursion Pharmaceuticals, Inc.2025Najat Khan600,0001,944,5472,501,058256,7775,349,065
17Quanterix Corporation2025Masoud Toloue670,9501,170,0002,729,998674,1725,250,745
18Pacific Biosciences of California, Inc.2025Christian Henry748,2501,151,0131,696,278714,3054,309,846
19bluebird bio, Inc.2023Andrew Obenshain681,657863,5901,142,440348,0243,049,181
20Voyager Therapeutics, Inc.2025Alfred Sandrock674,903611,900843,900361,9172,508,370
21Codexis, Inc.2025Alison Moore524,732255,9941,065,223463,1252,323,279

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Adaptive Biotechnologies Corpnot disclosedRSU 50 · PSU 50not disclosedSemler Brossy Consulting Group, LLC
Allogene Therapeutics, Inc.not disclosedOption 55 · RSU 25 · PSU 20not disclosedCompensia
bluebird bio, Inc.85%not disclosedYes — Relative Total Shareholder Return (rTSR)Aon plc (Human Capital Solutions practice)
CareDx, Inc.122%RSU 70 · PSU 30NoAlpine Rewards
Castle Biosciences, Inc.138%RSU 50 · PSU 50NoAON (AON's Human Capital Solutions Practice, a division of AON plc)
Codexis, Inc.95%not disclosednot disclosedPearl Meyer
Fulgent Genetics, Inc.120.7%PSU 60 · RSU 40NoUSI
Guardant Health, Inc.140%PSU 50 · RSU 50NoAon
Immunocore Holdings plc120%Options 70 · RSU 30not disclosedAon
Maravai LifeSciences Holdings, Inc.not disclosednot disclosedNoMeridian Compensation Partners, LLC
Mesa Laboratories, Inc.125%PSU 50 · RSU 50NoFrederic W. Cook & Co, Inc.
Myriad Genetics, Inc.89%RSU 50 · PSU 50YesMercer, LLC
Natera, Inc.131.1%PSU 50 · RSU 50NoAon
NeoGenomics, Inc.60%RSU 50 · Options 50not disclosedWTW
Pacific Biosciences of California, Inc.95%not disclosednot disclosedAon Human Capital Solutions
Quanterix Corporation95%Options 70 · RSU 30not disclosedPayGov
Recursion Pharmaceuticals, Inc.80%RSU 50 · Option 50not disclosedCompensia
Sage Therapeutics, Inc.80%not disclosedYes — TSR milestones / Relative TSR vs. Nasdaq Biotechnology IndexAlpine Rewards
Twist Bioscience Corporation129.6%PSU 50 · RSU 50Nonot disclosed
Veracyte, Inc.118%PSU 50 · RSU 50NoAon
Voyager Therapeutics, Inc.97.5%not disclosedNoAlpine Rewards, LLC

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Adaptive Biotechnologies Corp in fiscal 2025?
As disclosed, Chad Robins (Chief Executive Officer and Chairman) was the highest-paid executive at Adaptive Biotechnologies Corp in fiscal 2025, with total compensation of $9,081,690.
How does Adaptive Biotechnologies Corp's chief executive pay compare to its disclosed peer group?
As disclosed, Chad Robins's total compensation ranked at the 75th percentile of Adaptive Biotechnologies Corp's disclosed peer group.
What is Adaptive Biotechnologies Corp's CEO-to-median employee pay ratio?
As disclosed, Adaptive Biotechnologies Corp's CEO-to-median employee pay ratio was 47:1.
How did shareholders vote on Adaptive Biotechnologies Corp's executive compensation?
As disclosed, 96.67% of shareholders supported Adaptive Biotechnologies Corp's executive compensation in the latest say-on-pay vote.
How much does Adaptive Biotechnologies Corp spend in total on board compensation for fiscal 2025?
As disclosed, Adaptive Biotechnologies Corp reported total board compensation of $971,461 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Chad RobinsDEF 14A2026-04-240001193125-26-177409Section “Summary Compensation Table” · page 33. As printed: 9,081,690. Filing ↗machine: span 818708–818717
2Section 01, Harlan RobinsDEF 14A2026-04-240001193125-26-177409Section “Summary Compensation Table” · page 33. As printed: 8,509,575. Filing ↗
3Section 01, Julie RubinsteinDEF 14A2026-04-240001193125-26-177409Section “Summary Compensation Table” · page 33. As printed: 4,603,995. Filing ↗machine: span 949713–949722
4Section 01, Susan BobulskyDEF 14A2026-04-240001193125-26-177409Section “Summary Compensation Table” · page 33. As printed: 3,547,558. Filing ↗machine: span 884205–884214
5Section 01, Kyle PiskelDEF 14A2026-04-240001193125-26-177409Section “Summary Compensation Table” · page 33. As printed: 3,310,729. Filing ↗machine: span 851463–851472
6Section 03, Susan Bobulsky RSUDEF 14A1900-01-010001193125-26-177409Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗
7Section 03, Susan Bobulsky OPTIONDEF 14A1900-01-010001193125-26-177409Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1102002–1102009
8Section 03, Julie Rubinstein RSUDEF 14A1900-01-010001193125-26-177409Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗
9Section 03, Harlan Robins RSUDEF 14A1900-01-010001193125-26-177409Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗
10Section 03, Kyle Piskel RSUDEF 14A1900-01-010001193125-26-177409Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗
11Section 03, Chad Robins RSUDEF 14A1900-01-010001193125-26-177409Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1027377–1027386
12Section 03, Julie Rubinstein RSUDEF 14A1900-01-010001193125-26-177409Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1176833–1176842
13Section 03, Chad Robins RSUDEF 14A1900-01-010001193125-26-177409Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1038225–1038234
14Section 03, Harlan Robins RSUDEF 14A1900-01-010001193125-26-177409Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1144817–1144826
15Section 03, Susan Bobulsky RSUDEF 14A1900-01-010001193125-26-177409Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1112849–1112856
16Section 03, Kyle Piskel RSUDEF 14A1900-01-010001193125-26-177409Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1070188–1070197
17Section 07, pay ratioDEF 14A2026-04-240001193125-26-177409Section “CEO Pay Ratio”. As printed: 47 : 1. Filing ↗
18Section 08, Peter NeupertDEF 14A2026-04-240001193125-26-177409Section “Director Compensation”. As printed: 354,997. Filing ↗machine: span 415969–416178
19Section 08, Michelle GriffinDEF 14A2026-04-240001193125-26-177409Section “Director Compensation”. As printed: 329,997. Filing ↗machine: span 403684–403893
20Section 08, Robert HershbergDEF 14A2026-04-240001193125-26-177409Section “Director Compensation”. As printed: 324,997. Filing ↗machine: span 409832–410041
21Section 08, Katey OwenDEF 14A2026-04-240001193125-26-177409Section “Director Compensation”. As printed: 309,997. Filing ↗machine: span 422107–422316
22Section 08, Michael PelliniDEF 14A2026-04-240001193125-26-177409Section “Director Compensation”. As printed: 276,463. Filing ↗machine: span 428249–428458
23Section 08, Chad RobinsDEF 14A2026-04-240001193125-26-177409Section “Director Compensation”. As printed: 0. Filing ↗
24Section 02, Julie Rubinstein 2026-04-24Form 42026-04-240001780664-26-000030Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Julie Rubinstein 2026-04-24Form 42026-04-240001780664-26-000030Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Julie Rubinstein 2026-04-24Form 42026-04-240001780664-26-000030Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Julie Rubinstein 2026-04-27Form 42026-04-290001780664-26-000032Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Julie Rubinstein 2026-04-27Form 42026-04-290001780664-26-000032Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Julie Rubinstein 2026-04-27Form 42026-04-290001780664-26-000032Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Kyle Piskel 2026-05-18Form 42026-05-200001780662-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Francis Lo 2026-06-04Form 42026-06-080001780660-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Francis Lo 2026-06-04Form 42026-06-080001780660-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Francis Lo 2026-06-04Form 42026-06-080001780660-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Francis Lo 2026-06-04Form 42026-06-080001780660-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Francis Lo 2026-06-04Form 42026-06-080001780660-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Susan Bobulsky 2026-06-04Form 42026-06-080001820885-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Francis Lo 2026-06-04Form 42026-06-080001780660-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Francis Lo 2026-06-04Form 42026-06-080001780660-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Francis Lo 2026-06-04Form 42026-06-080001780660-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Francis Lo 2026-06-04Form 42026-06-080001780660-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Susan Bobulsky 2026-06-11Form 42026-06-150001820885-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Harlan S. Robins 2026-06-15Form 42026-06-170001780851-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Harlan S. Robins 2026-06-16Form 42026-06-170001780851-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Michelle Griffin 2026-06-25Form 42026-06-290001229765-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Michelle Griffin 2026-06-25Form 42026-06-290001229765-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Michelle Griffin 2026-06-25Form 42026-06-290001229765-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Susan Bobulsky 2026-06-25Form 42026-06-290001820885-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Sharon Benzeno 2026-06-26Form 42026-06-300001780854-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Sharon Benzeno 2026-06-26Form 42026-06-300001780854-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Sharon Benzeno 2026-06-26Form 42026-06-300001780854-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Sharon Benzeno 2026-06-29Form 42026-06-300001780854-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Sharon Benzeno 2026-06-29Form 42026-06-300001780854-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Sharon Benzeno 2026-06-29Form 42026-06-300001780854-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Sharon Benzeno 2026-06-29Form 42026-06-300001780854-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Sharon Benzeno 2026-06-29Form 42026-06-300001780854-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Sharon Benzeno 2026-06-29Form 42026-06-300001780854-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Sharon Benzeno 2026-06-29Form 42026-06-300001780854-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Sharon Benzeno 2026-06-29Form 42026-06-300001780854-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Sharon Benzeno 2026-06-29Form 42026-06-300001780854-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Francis Lo 2026-07-01Form 42026-07-060001780660-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Susan Bobulsky 2026-07-01Form 42026-07-060001820885-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Francis Lo 2026-07-01Form 42026-07-060001780660-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Francis Lo 2026-07-01Form 42026-07-060001780660-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Francis Lo 2026-07-01Form 42026-07-060001780660-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Francis Lo 2026-07-01Form 42026-07-060001780660-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Francis Lo 2026-07-01Form 42026-07-060001780660-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Francis Lo 2026-07-01Form 42026-07-060001780660-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Francis Lo 2026-07-01Form 42026-07-060001780660-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Francis Lo 2026-07-01Form 42026-07-060001780660-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Francis Lo 2026-07-01Form 42026-07-060001780660-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Francis Lo 2026-07-01Form 42026-07-060001780660-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Francis Lo 2026-07-01Form 42026-07-060001780660-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Francis Lo 2026-07-02Form 42026-07-060001780660-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Francis Lo 2026-07-02Form 42026-07-060001780660-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Harlan S. Robins 2026-07-02Form 42026-07-070001780851-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Francis Lo 2026-07-02Form 42026-07-060001780660-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Francis Lo 2026-07-02Form 42026-07-060001780660-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Francis Lo 2026-07-02Form 42026-07-060001780660-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Harlan S. Robins 2026-07-02Form 42026-07-070001780851-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Francis Lo 2026-07-02Form 42026-07-060001780660-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Francis Lo 2026-07-02Form 42026-07-060001780660-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Francis Lo 2026-07-15Form 42026-07-170001780660-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Francis Lo 2026-07-15Form 42026-07-170001780660-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Francis Lo 2026-07-15Form 42026-07-170001780660-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Francis Lo 2026-07-15Form 42026-07-170001780660-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Francis Lo 2026-07-15Form 42026-07-170001780660-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Francis Lo 2026-07-15Form 42026-07-170001780660-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Francis Lo 2026-07-15Form 42026-07-170001780660-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Susan Bobulsky 2026-07-16Form 42026-07-200001820885-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Harlan S. Robins 2026-07-21Form 42026-07-230001780851-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Harlan S. Robins 2026-07-21Form 42026-07-230001780851-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Harlan S. Robins 2026-07-21Form 42026-07-230001780851-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Harlan S. Robins 2026-07-21Form 42026-07-230001780851-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Susan Bobulsky 2026-07-30Form 42026-08-030001820885-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Susan Bobulsky 2026-08-10Form 42026-08-120001820885-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Peter Neupert 2026-08-17Form 42026-08-190001237566-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Peter Neupert 2026-08-17Form 42026-08-190001237566-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Peter Neupert 2026-08-17Form 42026-08-190001237566-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Peter Neupert 2026-08-17Form 42026-08-190001237566-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Chad M. Robins 2026-08-17Form 42026-08-190001780649-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Chad M. Robins 2026-08-17Form 42026-08-190001780649-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Peter Neupert 2026-08-17Form 42026-08-190001237566-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Chad M. Robins 2026-08-17Form 42026-08-190001780649-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Chad M. Robins 2026-08-17Form 42026-08-190001780649-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Chad M. Robins 2026-08-18Form 42026-08-190001780649-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Chad M. Robins 2026-08-18Form 42026-08-190001780649-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, Chad M. Robins 2026-08-18Form 42026-08-190001780649-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Chad M. Robins 2026-08-18Form 42026-08-190001780649-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Robert Hershberg 2026-08-18Form 42026-08-200001274139-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Robert Hershberg 2026-08-18Form 42026-08-200001274139-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Robert Hershberg 2026-08-18Form 42026-08-200001274139-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Robert Hershberg 2026-08-18Form 42026-08-200001274139-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Katey Owen 2026-08-26Form 42026-08-280001852578-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, Katey Owen 2026-08-31Form 42026-09-020001852578-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, Susan Bobulsky 2026-09-15Form 42026-09-170001820885-26-000023Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, Francis Lo 2026-09-16Form 42026-09-180001780660-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, Francis Lo 2026-09-16Form 42026-09-180001780660-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, Francis Lo 2026-09-16Form 42026-09-180001780660-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, Francis Lo 2026-09-16Form 42026-09-180001780660-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, Francis Lo 2026-09-16Form 42026-09-180001780660-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, Francis Lo 2026-09-16Form 42026-09-180001780660-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, Francis Lo 2026-09-16Form 42026-09-180001780660-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, Francis Lo 2026-09-16Form 42026-09-180001780660-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, Francis Lo 2026-09-16Form 42026-09-180001780660-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, Francis Lo 2026-09-16Form 42026-09-180001780660-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
126Section 02, Julie Rubinstein 2026-10-01Form 42026-10-050001780664-26-000035Insider equity transaction reported since the proxy statement. Filing ↗
127Section 02, Julie Rubinstein 2026-10-01Form 42026-10-050001780664-26-000035Insider equity transaction reported since the proxy statement. Filing ↗
128Section 02, Julie Rubinstein 2026-10-01Form 42026-10-050001780664-26-000035Insider equity transaction reported since the proxy statement. Filing ↗
129Section 02, Julie Rubinstein 2026-10-01Form 42026-10-050001780664-26-000035Insider equity transaction reported since the proxy statement. Filing ↗
130Section 02, Francis Lo 2026-10-01Form 42026-10-050001780660-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
131Section 02, Francis Lo 2026-10-01Form 42026-10-050001780660-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
132Section 02, Francis Lo 2026-10-01Form 42026-10-050001780660-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
133Section 02, Francis Lo 2026-10-01Form 42026-10-050001780660-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
134Section 02, Francis Lo 2026-10-01Form 42026-10-050001780660-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
135Section 02, Francis Lo 2026-10-01Form 42026-10-050001780660-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
136Section 02, Francis Lo 2026-10-01Form 42026-10-050001780660-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
137Section 02, Francis Lo 2026-10-01Form 42026-10-050001780660-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
138Section 02, Julie Rubinstein 2026-10-02Form 42026-10-050001780664-26-000035Insider equity transaction reported since the proxy statement. Filing ↗
139Section 02, Julie Rubinstein 2026-10-02Form 42026-10-050001780664-26-000035Insider equity transaction reported since the proxy statement. Filing ↗
140Section 02, Julie Rubinstein 2026-10-02Form 42026-10-050001780664-26-000035Insider equity transaction reported since the proxy statement. Filing ↗
141Section 02, Julie Rubinstein 2026-10-05Form 42026-10-050001780664-26-000035Insider equity transaction reported since the proxy statement. Filing ↗
142Section 02, Julie Rubinstein 2026-10-05Form 42026-10-050001780664-26-000035Insider equity transaction reported since the proxy statement. Filing ↗
143Section 02, Julie Rubinstein 2026-10-05Form 42026-10-050001780664-26-000035Insider equity transaction reported since the proxy statement. Filing ↗
144Section 02, Julie Rubinstein 2026-10-05Form 42026-10-050001780664-26-000035Insider equity transaction reported since the proxy statement. Filing ↗
145Section 02, Julie Rubinstein 2026-10-06Form 42026-10-080001780664-26-000037Insider equity transaction reported since the proxy statement. Filing ↗
146Section 02, Julie Rubinstein 2026-10-06Form 42026-10-080001780664-26-000037Insider equity transaction reported since the proxy statement. Filing ↗
147Section 02, Julie Rubinstein 2026-10-06Form 42026-10-080001780664-26-000037Insider equity transaction reported since the proxy statement. Filing ↗
148Section 02, Julie Rubinstein 2026-10-06Form 42026-10-080001780664-26-000037Insider equity transaction reported since the proxy statement. Filing ↗
149Section 02, Julie Rubinstein 2026-10-06Form 42026-10-080001780664-26-000037Insider equity transaction reported since the proxy statement. Filing ↗
150Section 02, Julie Rubinstein 2026-10-06Form 42026-10-080001780664-26-000037Insider equity transaction reported since the proxy statement. Filing ↗
151Section 02, Susan Bobulsky 2026-10-06Form 42026-10-080001820885-26-000025Insider equity transaction reported since the proxy statement. Filing ↗
152Section 02, Julie Rubinstein 2026-10-07Form 42026-10-080001780664-26-000037Insider equity transaction reported since the proxy statement. Filing ↗
153Section 02, Julie Rubinstein 2026-10-07Form 42026-10-080001780664-26-000037Insider equity transaction reported since the proxy statement. Filing ↗
154Section 02, Julie Rubinstein 2026-10-07Form 42026-10-080001780664-26-000037Insider equity transaction reported since the proxy statement. Filing ↗
155Section 02, Julie Rubinstein 2026-10-08Form 42026-10-080001780664-26-000037Insider equity transaction reported since the proxy statement. Filing ↗
156Section 02, Julie Rubinstein 2026-10-08Form 42026-10-080001780664-26-000037Insider equity transaction reported since the proxy statement. Filing ↗
157Section 02, Julie Rubinstein 2026-10-08Form 42026-10-080001780664-26-000037Insider equity transaction reported since the proxy statement. Filing ↗
158Section 02, Julie Rubinstein 2026-10-09Form 42026-10-130001780664-26-000039Insider equity transaction reported since the proxy statement. Filing ↗
159Section 02, Julie Rubinstein 2026-10-09Form 42026-10-130001780664-26-000039Insider equity transaction reported since the proxy statement. Filing ↗
160Section 02, Julie Rubinstein 2026-10-09Form 42026-10-130001780664-26-000039Insider equity transaction reported since the proxy statement. Filing ↗
161Section 02, Julie Rubinstein 2026-10-12Form 42026-10-130001780664-26-000039Insider equity transaction reported since the proxy statement. Filing ↗
162Section 02, Julie Rubinstein 2026-10-12Form 42026-10-130001780664-26-000039Insider equity transaction reported since the proxy statement. Filing ↗
163Section 02, Julie Rubinstein 2026-10-12Form 42026-10-130001780664-26-000039Insider equity transaction reported since the proxy statement. Filing ↗
164Section 02, Julie Rubinstein 2026-10-12Form 42026-10-130001780664-26-000039Insider equity transaction reported since the proxy statement. Filing ↗
165Section 02, Julie Rubinstein 2026-10-13Form 42026-10-130001780664-26-000039Insider equity transaction reported since the proxy statement. Filing ↗
166Section 02, Julie Rubinstein 2026-10-13Form 42026-10-130001780664-26-000039Insider equity transaction reported since the proxy statement. Filing ↗
167Section 02, Julie Rubinstein 2026-10-13Form 42026-10-130001780664-26-000039Insider equity transaction reported since the proxy statement. Filing ↗
168Section 02, Julie Rubinstein 2026-10-14Form 42026-10-160001780664-26-000041Insider equity transaction reported since the proxy statement. Filing ↗
169Section 02, Julie Rubinstein 2026-10-14Form 42026-10-160001780664-26-000041Insider equity transaction reported since the proxy statement. Filing ↗
170Section 02, Julie Rubinstein 2026-10-14Form 42026-10-160001780664-26-000041Insider equity transaction reported since the proxy statement. Filing ↗
171Section 02, Julie Rubinstein 2026-10-14Form 42026-10-160001780664-26-000041Insider equity transaction reported since the proxy statement. Filing ↗
172Section 02, Julie Rubinstein 2026-10-15Form 42026-10-160001780664-26-000041Insider equity transaction reported since the proxy statement. Filing ↗
173Section 02, Julie Rubinstein 2026-10-15Form 42026-10-160001780664-26-000041Insider equity transaction reported since the proxy statement. Filing ↗
174Section 02, Julie Rubinstein 2026-10-15Form 42026-10-160001780664-26-000041Insider equity transaction reported since the proxy statement. Filing ↗
175Section 02, Julie Rubinstein 2026-10-16Form 42026-10-160001780664-26-000041Insider equity transaction reported since the proxy statement. Filing ↗
176Section 02, Julie Rubinstein 2026-10-16Form 42026-10-160001780664-26-000041Insider equity transaction reported since the proxy statement. Filing ↗
177Section 02, Julie Rubinstein 2026-10-16Form 42026-10-160001780664-26-000041Insider equity transaction reported since the proxy statement. Filing ↗
178Section 02, Julie Rubinstein 2026-10-16Form 42026-10-160001780664-26-000041Insider equity transaction reported since the proxy statement. Filing ↗
179Section 06, 2026 voteForm 8-K2026-06-090001193125-26-263844Item 5.07 · say-on-pay result. As reported: 96.67% (votes for as printed: 125,287,618). Filing ↗
180Section 06, 2025 voteForm 8-K2025-06-120001193125-25-140017Item 5.07 · say-on-pay result. As reported: 98.76% (votes for as printed: 126,126,999). Filing ↗
181Section 06, 2024 voteForm 8-K2024-06-110000950170-24-071913Item 5.07 · say-on-pay result. As reported: 87.05% (votes for as printed: 103,594,016). Filing ↗
182Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
183Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
184Section 09b board cost (computed)Computed——Cash 346,466 + equity 624,995 + all other 0 = 971,461, summed across the director compensation table rows.machine: formula: Σ = 971,461
185Natera, Inc., Section 10b CEO totalDEF 14A2026-04-230001104659-26-047770CEO total compensation as printed in Natera, Inc.'s own proxy. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878
186Twist Bioscience Corporation, Section 10b CEO totalDEF 14A2026-01-060001581280-26-000006CEO total compensation as printed in Twist Bioscience Corporation's own proxy. As printed: 13,781,570. Filing ↗machine: t34 · r2 · c15 · span 1510951–1510961
187Immunocore Holdings plc, Section 10b CEO totalDEF 14A2026-04-160001140361-26-015122CEO total compensation as printed in Immunocore Holdings plc's own proxy. As printed: 10,885,268. Filing ↗machine: r2 · c24 · span 670285–670295
188Maravai LifeSciences Holdings, Inc., Section 10b CEO totalDEF 14A2026-04-240001823239-26-000014CEO total compensation as printed in Maravai LifeSciences Holdings, Inc.'s own proxy. As printed: 10,129,708. Filing ↗machine: t21 · r3 · c20 · span 502645–502655
189NeoGenomics, Inc., Section 10b CEO totalDEF 14A2026-04-060001077183-26-000014CEO total compensation as printed in NeoGenomics, Inc.'s own proxy. As printed: 9,127,092. Filing ↗machine: r2 · c45 · span 869460–869469
190Adaptive Biotechnologies Corp (subject), Section 10b CEO totalDEF 14A2026-04-240001193125-26-177409CEO total compensation as printed in Adaptive Biotechnologies Corp's own proxy. As printed: 9,081,690. Filing ↗machine: span 818708–818717
191Guardant Health, Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-187403CEO total compensation as printed in Guardant Health, Inc.'s own proxy. As printed: 8,661,227. Filing ↗machine: r7 · c31 · span 773149–773158
192Veracyte, Inc., Section 10b CEO totalDEF 14A2026-04-220001384101-26-000021CEO total compensation as printed in Veracyte, Inc.'s own proxy. As printed: 7,421,877. Filing ↗machine: r4 · c27 · span 855413–855422
193CareDx, Inc., Section 10b CEO totalDEF 14A2026-04-270001217234-26-000028CEO total compensation as printed in CareDx, Inc.'s own proxy. As printed: 7,179,699. Filing ↗machine: t113 · r3 · c9 · span 1893652–1893661
194Sage Therapeutics, Inc., Section 10b CEO totalDEF 14A2025-04-240000950170-25-058060CEO total compensation as printed in Sage Therapeutics, Inc.'s own proxy. As printed: 7,112,589. Filing ↗machine: r4 · c28 · span 1143784–1143793
195Castle Biosciences, Inc., Section 10b CEO totalDEF 14A2026-04-080001628280-26-024166CEO total compensation as printed in Castle Biosciences, Inc.'s own proxy. As printed: 6,786,771. Filing ↗machine: r3 · c24 · span 933087–933096
196Mesa Laboratories, Inc., Section 10b CEO totalDEF 14A2026-07-220000724004-26-000071CEO total compensation as printed in Mesa Laboratories, Inc.'s own proxy. As printed: 6,643,208. Filing ↗machine: r3 · c24 · span 580946–580955
197Fulgent Genetics, Inc., Section 10b CEO totalDEF 14A2026-03-310001674930-26-000020CEO total compensation as printed in Fulgent Genetics, Inc.'s own proxy. As printed: 6,207,000. Filing ↗machine: r3 · c22 · span 533279–533288
198Allogene Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-300001628280-26-028948CEO total compensation as printed in Allogene Therapeutics, Inc.'s own proxy. As printed: 6,136,093. Filing ↗machine: r2 · c54 · span 451014–451023
199Myriad Genetics, Inc., Section 10b CEO totalDEF 14A2026-04-140000899923-26-000031CEO total compensation as printed in Myriad Genetics, Inc.'s own proxy. As printed: 5,686,740. Filing ↗machine: r2 · c24 · span 792986–792996
200Recursion Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-300001601830-26-000065CEO total compensation as printed in Recursion Pharmaceuticals, Inc.'s own proxy. As printed: 5,349,065. Filing ↗machine: r5 · c24 · span 551909–551918
201Quanterix Corporation, Section 10b CEO totalDEF 14A2026-04-240001104659-26-048166CEO total compensation as printed in Quanterix Corporation's own proxy. As printed: 5,250,745. Filing ↗machine: t18 · r1 · c47 · span 503076–503085
202Pacific Biosciences of California, Inc., Section 10b CEO totalDEF 14A2026-04-230001299130-26-000064CEO total compensation as printed in Pacific Biosciences of California, Inc.'s own proxy. As printed: 4,309,846. Filing ↗machine: r2 · c48 · span 876974–876983
203bluebird bio, Inc., Section 10b CEO totalDEF 14A2024-09-260001293971-24-000049CEO total compensation as printed in bluebird bio, Inc.'s own proxy. As printed: 3,049,181. Filing ↗machine: r2 · c21 · span 402787–402796
204Voyager Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-280001104659-26-050297CEO total compensation as printed in Voyager Therapeutics, Inc.'s own proxy. As printed: 2,508,370. Filing ↗machine: t9 · r1 · c47 · span 370852–370861
205Codexis, Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-186994CEO total compensation as printed in Codexis, Inc.'s own proxy. As printed: 2,323,279. Filing ↗machine: r2 · c27 · span 319928–319937
206Section 10a, Sage Therapeutics, Inc. reciprocityDEF 14A—0000950170-25-058060Sage Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Adaptive Biotechnologies Corp. Filing ↗
207Section 10a, Quanterix Corporation reciprocityDEF 14A—0001104659-26-048166Quanterix Corporation names Adaptive Biotechnologies Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
208Section 10a, Voyager Therapeutics, Inc. reciprocityDEF 14A—0001104659-26-050297Voyager Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Adaptive Biotechnologies Corp. Filing ↗
209Section 10a, Immunocore Holdings plc reciprocityDEF 14A—0001140361-26-015122Immunocore Holdings plc's most recent proxy was read; its disclosed peer group does not include Adaptive Biotechnologies Corp. Filing ↗
210Section 10a, Natera, Inc. reciprocityDEF 14A—0001104659-26-047770Natera, Inc.'s most recent proxy was read; its disclosed peer group does not include Adaptive Biotechnologies Corp. Filing ↗
211Section 10a, Allogene Therapeutics, Inc. reciprocityDEF 14A—0001628280-26-028948Allogene Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Adaptive Biotechnologies Corp. Filing ↗
212Section 10a, CareDx, Inc. reciprocityDEF 14A—0001217234-26-000028CareDx, Inc. names Adaptive Biotechnologies Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
213Section 10a, Castle Biosciences, Inc. reciprocityDEF 14A—0001628280-26-024166Castle Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Adaptive Biotechnologies Corp. Filing ↗
214Section 10a, Codexis, Inc. reciprocityDEF 14A—0001193125-25-093503Codexis, Inc.'s most recent proxy was read; its disclosed peer group does not include Adaptive Biotechnologies Corp. Filing ↗
215Section 10a, Fulgent Genetics, Inc. reciprocityDEF 14A—0001674930-26-000020Fulgent Genetics, Inc. names Adaptive Biotechnologies Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
216Section 10a, Guardant Health, Inc. reciprocityDEF 14A—0001193125-26-187403Guardant Health, Inc.'s most recent proxy was read; its disclosed peer group does not include Adaptive Biotechnologies Corp. Filing ↗
217Section 10a, Maravai LifeSciences Holdings, Inc. reciprocityDEF 14A—0001823239-26-000014Maravai LifeSciences Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Adaptive Biotechnologies Corp. Filing ↗
218Section 10a, Mesa Laboratories, Inc. reciprocityDEF 14A—0000724004-26-000071Mesa Laboratories, Inc. names Adaptive Biotechnologies Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
219Section 10a, NeoGenomics, Inc. reciprocityDEF 14A—0001077183-26-000014NeoGenomics, Inc. names Adaptive Biotechnologies Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
220Section 10a, Pacific Biosciences of California, Inc. reciprocityDEF 14A—0001299130-26-000064Pacific Biosciences of California, Inc. names Adaptive Biotechnologies Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
221Section 10a, Veracyte, Inc. reciprocityDEF 14A—0001384101-26-000021Veracyte, Inc. names Adaptive Biotechnologies Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.

Get the Adaptive Biotechnologies Corp Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
ADPT Peer Teardown Report